Evolus Inc (EOLS) - Total Assets
Based on the latest financial reports, Evolus Inc (EOLS) holds total assets worth $248.02 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Evolus Inc - Total Assets Trend (2015–2025)
This chart illustrates how Evolus Inc's total assets have evolved over time, based on quarterly financial data. Also see Evolus Inc market capitalisation for the company's overall valuation and market capitalisation.
Evolus Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Evolus Inc's total assets of $248.02 Million consist of 63.3% current assets and 36.7% non-current assets. Review EOLS total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.8% |
| Accounts Receivable | $54.70 Million | 24.2% |
| Inventory | $26.96 Million | 11.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $48.04 Million | 21.3% |
| Goodwill | $21.21 Million | 9.4% |
Asset Composition Trend (2015–2025)
This chart illustrates how Evolus Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Evolus Inc stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evolus Inc's current assets represent 63.3% of total assets in 2025, an increase from 4.9% in 2015.
- Cash Position: Cash and equivalents constituted 23.8% of total assets in 2025, up from 4.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, a decrease from 94.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 24.2% of total assets.
Evolus Inc Competitors by Total Assets
Key competitors of Evolus Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Evolus Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.70 | 2.27 | 1.94 |
| Quick Ratio | 1.28 | 1.86 | 1.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $68.81 Million | $81.22 Million | $67.04 Million |
Evolus Inc - Advanced Valuation Insights
This section examines the relationship between Evolus Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 53.71 |
| Latest Market Cap to Assets Ratio | 2.31 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | $225.87 Million |
| Market Capitalization | $522.46 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Evolus Inc's assets at a significant premium (2.31x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Evolus Inc's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Evolus Inc (2015–2025)
The table below shows the annual total assets of Evolus Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $225.87 Million | -2.88% |
| 2024-12-31 | $232.57 Million | +23.05% |
| 2023-12-31 | $189.00 Million | +6.19% |
| 2022-12-31 | $177.98 Million | -30.88% |
| 2021-12-31 | $257.48 Million | +23.16% |
| 2020-12-31 | $209.07 Million | -13.05% |
| 2019-12-31 | $240.44 Million | +39.92% |
| 2018-12-31 | $171.84 Million | +12.88% |
| 2017-12-31 | $152.23 Million | +96.44% |
| 2016-12-31 | $77.50 Million | -4.68% |
| 2015-12-31 | $81.30 Million | -- |
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels,… Read more